ADC Therapeutics 
Welcome,         Profile    Billing    Logout  
 4 Products   4 Diseases   4 Products   1 Trial   222 News 


123»
  • ||||||||||  ADCT-701 / ADC Therapeutics
    Enrollment open, Trial completion date, Trial primary completion date:  Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas (clinicaltrials.gov) -  Apr 9, 2024   
    P1,  N=70, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Oct 2029 | Trial primary completion date: Oct 2026 --> Oct 2027
  • ||||||||||  ADCT-701 / ADC Therapeutics, Lysodren (mitotane) / Perrigo Company
    Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinoma (Room 5 - Upper Level - Convention Center) -  Mar 5, 2024 - Abstract #AACR2024AACR_8802;    
    P1
    In vivo studies showed that ADCT-701 was highly effective against DLK1-positive ACC xenografts and PDX models with durable anti-tumor activity. Our pre-clinical data demonstrate DLK1 as an important therapeutic target in ACC and support an upcoming phase I clinical trial of ADCT-701 in patients with neuroendocrine tumors including ACC (NCT06041516).
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics, Keytruda (pembrolizumab) / Merck (MSD)
    MODULE 6: Current and Future Management of R/R HL (Omni San Diego, Grand Ballroom (Level 2), 4) -  Oct 22, 2023 - Abstract #ASH2023ASH_597;    
    Supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck and Seagen Inc. Potential role of BV alone or in combination with chemotherapy or immune checkpoint inhibition as a bridge to transplant Key efficacy and safety findings from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for R/R HL; implications for clinical practice Published data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with other systemic approaches for R/R HL, such as BV or chemotherapy Mechanism of action and structural components of the novel antibody-drug conjugate camidanlumab tesirine Principal efficacy and safety findings from the pivotal Phase II study of camidanlumab tesirine for patients with heavily pretreated HL; potential role in practice Other promising agents/strategies for patients with HL (eg, investigational immune checkpoint inhibitors, CAR T-cell therapy)
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) -  May 12, 2023   
    P2,  N=3, Terminated, 
    No abstract available N=10 --> 3 | Trial completion date: Dec 2024 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Nov 2022; ADCT is reallocating all resources to the phase III program.
  • ||||||||||  Review, Journal, CAR T-Cell Therapy:  Immunotherapy for Hodgkin lymphoma: from monoclonal antibodies to chimeric antigen receptor T-cell therapy. (Pubmed Central) -  Jan 27, 2023   
    Additionally, studies examining combination strategies with the goal of reducing the risk of relapse and chemotherapy-related toxicity have showed encouraging results, mainly in untreated early unfavorable or advanced stage classical HL (cHL). Other non-approved immunotherapies such as camidanlumab tesirine, bispecific CD30/CD16A antibody, and CD30 chimeric antigen receptor (CAR) T-cell therapy are promising approaches that may reinforce the therapeutic arsenal available to patients.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Trial completion date, Trial termination, Monotherapy, Metastases:  Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) -  Dec 15, 2022   
    P1b,  N=78, Terminated, 
    Trial completion date: Nov 2023 --> Nov 2022 | Recruiting --> Terminated; Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics, Adcetris (brentuximab vedotin) / Seagen, Takeda, AFM13 / Affimed
    Journal:  Current salvage therapies in Hodgkin lymphoma. (Pubmed Central) -  Jun 4, 2022   
    There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.
  • ||||||||||  MEDI3726 / ADC Therapeutics, AstraZeneca, MLN2704 / Takeda
    Review, Journal, IO biomarker:  Advances in PSMA-targeted therapy for prostate cancer. (Pubmed Central) -  Apr 22, 2022   
    Currently, a great deal of evidence suggests that significant progresses have been made in the PSMA-targeted therapy of PCa. Herein, different PSMA-targeted therapies for PCa are reviewed, including radioligand therapy (Lu-PSMA-RLT, Ac-PSMA-RLT), antibody-drug conjugates (MLN2704, PSMA-MMAE, MEDI3726), cellular immunotherapy (CAR-T, CAR/NK-92, PSMA-targeted BiTE), photodynamic therapy, imaging-guided surgery (radionuclide-guided surgery, fluorescence-guided surgery, multimodal imaging-guided surgery), and ultrasound-mediated nanobubble destruction.
  • ||||||||||  Journal:  Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. (Pubmed Central) -  Feb 1, 2022   
    Reviewing the clinical efficacy and safety data from almost forty clinical trials of PBD dimer-containing ADCs highlights the complexities and challenges of ADC early clinical development. It enables some conclusions to be made about reasons for failure and suggests strategies to optimise the future clinical development of this promising class of ADCs in a rapidly expanding field.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Enrollment open, Trial completion date, Trial primary completion date:  ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) -  Jan 25, 2022   
    P2,  N=10, Recruiting, 
    It enables some conclusions to be made about reasons for failure and suggests strategies to optimise the future clinical development of this promising class of ADCs in a rapidly expanding field. Not yet recruiting --> Recruiting | Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Classical Hodgkin Lymphoma: Answers to the Important Management Questions in 2021 () -  Sep 6, 2021 - Abstract #SOHO2021SOHO_396;    
    The addition of brentuximab vedotin in the management of early-stage HL is investigational, but the phase Iidata are encouraging, and a randomized study comparing ABVD ×3 ± RT versus BV-AVD ×3 ± RT is beginning...ABVD for 2 cycles is initiated, and if there is an excellent response, then it is continued for 4 more cycles, many times dropping bleomycin...Although a subsequent study comparing BV-AVD to PET-adapted therapy is not planned, there is an ongoing study comparing BV-AVD to nivolumab-AVD that is nearly 50% accrued...Prior to the introduction of BV and CPI, patients requiring salvage therapy typically received combination treatment that included cisplatin or carboplatin, such as ICE or DHAP...Camidanlumab Tesirine, a human IgG1 anti-CD25 antibody- drug conjugate, has a different warhead than BV...AFM13 was first studied in HL patients as monotherapy in a dose-escalating phase 1 clinical study for patients with heavily pre-treated HL with minimal efficacy, but in combination with pembrolizumab, the response rate was reasonable, albeit with four deaths on study, mostly related to end- stage lymphoma...The number of patients treated with a CD30 CART cells is limited, and early on, the results were inferior to those of CD19 CART cells in diffuse large B cell lymphoma, but after the addition of lymphodepleting chemotherapy, the CR rate is much better. Because of its safety profile, many recommend this treatment prior to an allogeneic stem cell transplant.
  • ||||||||||  Journal, Checkpoint inhibition:  Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. (Pubmed Central) -  Aug 18, 2021   
    The field of immunotherapy in cHL is now moving toward combinations of PD-1 inhibitors with other immunological agents such as cytotoxic T- lymphocyte associated protein-4 (CTLA-4) inhibitors, newer PD-1 inhibitors such as sintilimab, tislelizumab, avelumab and camrelizumab, bispecific antibodies such as AFM-13, cellular therapies using CD30 chimeric antigen T-cells (CD30.CART) and anti-CD25 antibody-drug conjugates such as camidanlumab tesirine (cami-T). Here we review early phase studies evaluating these approaches in the treatment of cHL.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Review, Journal:  A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. (Pubmed Central) -  Aug 4, 2021   
    The toxicity profile was similar to that seen in the phase 1 study, with no new safety signals.. As the phase 2 study with Cami is continuing to accrue patients and we await the final results, the preliminary results with Cami are encouraging and provide an additional therapeutic option especially for patients with multiply relapsed/refractory cHL and perhaps other hematological malignancies expression CD25.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics, ADCT-502 / ADC Therapeutics, Lonca-T (loncastuximab tesirine) / Overland ADCT BioPharma
    Preclinical, Journal:  The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates. (Pubmed Central) -  Jun 30, 2021   
    These include ADCT-301 (camidanlumab tesirine) and ADCT-402 (loncastuximab tesirine) in pivotal phase II trials that contain the payload tesirine, which releases the PBD dimer warhead SG3199...The level of resistance achieved was approximately 3,000-fold for ADCT-301 and 3-fold for SG3199 in Karpas-299, and 8-fold for ADCT-502 and 4-fold for SG3199 in NCI-N87...These data show that acquired resistance to PBD-ADCs and SG3199 can involve specific ATP-binding cassette (ABC) drug transporters. This has clinical implications as potential biomarkers of resistance and for the rational design of drug combinations.
  • ||||||||||  [VIRTUAL] From Biology to Therapy: Progress in Hodgkin Lymphoma () -  May 20, 2021 - Abstract #SOHO2021SOHO_249;    
    The field of immunotherapy in classic HL is now moving toward the use of newer PD-1 inhibitors such as sintilimab, tislelizumab and camrelizumab,21–23 bispecific antibodies such as AFM-13,24 cellular therapies using CD30 chimeric antigen T-cells (CD30.CART)25 and anti-CD25 antibody-drug conjugates such as camidanlumab tesirine (cami-T).26 These therapies engage other cells within the microenvironment, deplete regulatory T-cells, or activate T-cells despite loss of MHC molecules...Future studies are required to understand which drugs to use together but also the sequence in which they should be administered. A rational approach to combining targeted agents with standard therapies will likely result in an improved outcome for patients.
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) -  Jan 22, 2021   
    P1b,  N=95, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2022
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    Trial completion date, Trial initiation date, Trial primary completion date:  ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) -  Jan 13, 2021   
    P2,  N=10, Not yet recruiting, 
    Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2022 Trial completion date: Nov 2023 --> Feb 2024 | Initiation date: Dec 2020 --> Mar 2021 | Trial primary completion date: Nov 2023 --> Feb 2024
  • ||||||||||  camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
    New P2 trial:  ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) -  Nov 20, 2020   
    P2,  N=10, Not yet recruiting,